SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Babe Didrikson Zaharias Synthetic CCD

PatientMildred Ella Didrikson Zaharias
Date of birth1984-06-26
IdentifiersMRN HR-ML038-SYN; SSN (made up) 000-38-4471
Document date2026-11-01
AuthorRosalind Vasquez-Thornbury, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Three months of rectal bleeding, narrower stools and urgency, with tiredness, in a professional golfer of 41: examination, blood tests, and colonoscopy this week. Concerns: Bright red blood with most bowel movements for about three months, stools narrower than before, urgency and a feeling of not having finished; more tired than usual on the course since the end of last season; A walk-in clinic put the bleeding down to hemorrhoids two months ago and gave her a cream; she is 41, below the age at which screening starts, and was not examined; She wants to keep competing, and wants to know at once whether whatever this is will mean a colostomy. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morningOne tablet every other morningOral route2026-03-30activeS
Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months)500 mg every 3 weeks for nine dosesIntravenous route2026-04-06 to 2026-09-21completedS
Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from ironOne tablet each morningOral route2026-06-29activeS

Procedures

ProcedureDatesStatusEvidence
Colonoscopy to the cecum with biopsy, under sedation: an ulcerated, friable mass on the posterior and left lateral wall of the lower rectum, about half the circumference, from 4 to 9 cm from the anal verge, not obstructing; six biopsies; the rest of the colon normal; no polyps. Pathology: invasive adenocarcinoma, moderately differentiated; immunohistochemistry shows loss of MSH2 and MSH6 with MLH1 and PMS2 retained; microsatellite instability high by PCR2026-03-19 to 2026-03-19completedS
Rectal-protocol MRI of the pelvis (high-resolution T2 and diffusion-weighted): low rectal tumor, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, posterior and left lateral, extending 4 mm beyond the muscularis propria (cT3b); two mesorectal lymph nodes of 7 mm with irregular borders (cN1); mesorectal fascia clear by 6 mm; no extramural venous invasion; no lateral pelvic nodes; sphincter complex not involved2026-03-24 to 2026-03-24completedS
CT of the chest, abdomen and pelvis with contrast: no liver, lung or peritoneal metastases; no enlarged retroperitoneal nodes2026-03-25 to 2026-03-25completedS
Colorectal multidisciplinary tumor board (medical oncology, colorectal surgery, radiation oncology, radiology, pathology, genetics, wound-ostomy nursing, nurse navigator): mismatch repair-deficient low rectal adenocarcinoma, cT3bN1M0; surgery would most likely need an abdominoperineal resection with a permanent colostomy; recommends PD-1 blockade with dostarlimab for six months, restaging by MRI and endoscopy about every three months, and watch-and-wait if there is a clinical complete response, with chemoradiation and surgery kept in reserve2026-03-27 to 2026-03-27completedS
Chest X-ray, two views: clear lungs, no consolidation, ground-glass change or effusion2026-06-01 to 2026-06-01completedS
Advance care planning conversation, about 20 minutes2026-08-10 to 2026-08-10completedS
Genetic counseling before germline testing: three-generation pedigree as she knows it, consent, and an explanation of what a positive or negative result would mean for her and her blood relatives2026-03-30 to 2026-03-30completedS
Restaging rectal-protocol MRI of the pelvis after four doses: marked regression, with low-signal fibrosis replacing most of the tumor and a small focus of intermediate signal with slight restricted diffusion at the lower margin; mesorectal nodes now 3 mm and smooth; near-complete response2026-06-24 to 2026-06-24completedS
Restaging flexible sigmoidoscopy after four doses: a flat white scar where the tumor was, with a 5 mm shallow ulcer at its lower edge; no mass2026-06-25 to 2026-06-25completedS
Final restaging rectal-protocol MRI of the pelvis after nine doses: low-signal fibrosis only, no intermediate signal and no restricted diffusion; no suspicious lymph nodes; complete response on MRI2026-09-28 to 2026-09-28completedS
Final restaging CT of the chest, abdomen and pelvis with contrast: no metastases2026-09-28 to 2026-09-28completedS
Final restaging flexible sigmoidoscopy after nine doses: a flat white scar with fine surface vessels; no ulcer, nodularity or mass; complete endoscopic response2026-09-29 to 2026-09-29completedS

Immunizations

DateVaccineStatusEvidence
2021-05-10Tdap vaccinecompletedS
2026-08-10Hepatitis B vaccine (adjuvanted, two-dose series), dose 1completedS
2026-09-21Hepatitis B vaccine (adjuvanted, two-dose series), dose 2, given in the infusion center with the last dose of dostarlimabcompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

No historical medical events are recorded.

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Bright red blood with most bowel movements for about three months, stools narrower than before, urgency and a feeling of not having finished; more tired than usual on the course since the end of last seasonactiveS
A walk-in clinic put the bleeding down to hemorrhoids two months ago and gave her a cream; she is 41, below the age at which screening starts, and was not examinedactiveS
She wants to keep competing, and wants to know at once whether whatever this is will mean a colostomyactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 13.4 on 2026-10-05; MCV [Entitic mean volume] in Red Blood Cells by Automated count 86 on 2026-10-05; Leukocytes [#/volume] in Blood by Automated count 6.1 on 2026-10-05; Platelets [#/volume] in Blood by Automated count 255 on 2026-10-05; Ferritin [Mass/volume] in Serum or Plasma 41 on 2026-10-05; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-06-29; Potassium [Moles/volume] in Serum or Plasma 4.2 on 2026-06-29; Creatinine [Mass/volume] in Serum or Plasma 0.77 on 2026-10-05; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 99 on 2026-10-05; Glucose [Mass/volume] in Serum or Plasma 89 on 2026-06-29; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 on 2026-10-05; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 2026-10-05; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 70 on 2026-06-29; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 2026-06-29; Albumin [Mass/volume] in Serum or Plasma 4.4 on 2026-06-29; Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 1.6 on 2026-10-05; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-03-16; Thyrotropin [Units/volume] in Serum or Plasma 2.4 on 2026-10-05; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 on 2026-10-05; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-10-05; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 on 2026-10-05 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this weekresolvedconfirmed K62.5S — Synthetic presenting problem anchored to the documented fatigue before her cancer diagnosis. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tirednessactiveconfirmed D50.0S — Synthetic finding anchored to the documented fatigue at the end of the 1952 season.
Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactlyactiveconfirmed C20S — Synthetic histology, site, stage, mismatch repair status and course; the sources say she had cancer treated with a colostomy and call it colon cancer (R on the site). See sources.md.
Acute viral upper respiratory infection with cough and sore throat, a week before cycle 4 of dostarlimab; oxygen saturation and chest X-ray normal, so immune-related pneumonitis is unlikely; rapid influenza and COVID-19 tests negative; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness; not a historical claim.
Immune-related primary hypothyroidism from dostarlimab, grade 2: tiredness and cold hands, TSH 12.6 mIU/L and free T4 0.6 ng/dL after four doses, following a mild TSH rise four weeks earlier; dostarlimab continuedactiveconfirmed E03.2S — Synthetic common immune-related adverse event of PD-1 blockade.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-16Hemoglobin [Mass/volume] in Blood11g/dL12-15.5 g/dLLowS
2026-03-16MCV [Entitic mean volume] in Red Blood Cells by Automated count77fL80-100 fLLowS
2026-03-16Leukocytes [#/volume] in Blood by Automated count6.810*3/uL4-11 10*3/uLNormalS
2026-03-16Platelets [#/volume] in Blood by Automated count41210*3/uL150-400 10*3/uLHighS
2026-03-16Ferritin [Mass/volume] in Serum or Plasma9ng/mL15-150 ng/mLLowS
2026-03-16Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-16Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
2026-03-16Creatinine [Mass/volume] in Serum or Plasma0.78mg/dL0.59-1.04 mg/dLNormalS
2026-03-16Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M98mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-16Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS
2026-03-16Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
2026-03-16Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L8-35 U/LNormalS
2026-03-16Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma72U/L35-104 U/LNormalS
2026-03-16Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-03-16Albumin [Mass/volume] in Serum or Plasma4.3g/dL3.5-5 g/dLNormalS
2026-03-16Carcinoembryonic Ag [Mass/volume] in Serum or Plasma5.8ng/mLUp to 3.0 ng/mL in non-smokersHighS
2026-03-16Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-03-30Hemoglobin [Mass/volume] in Blood11.1g/dL12-15.5 g/dLLowS
2026-03-30Leukocytes [#/volume] in Blood by Automated count6.510*3/uL4-11 10*3/uLNormalS
2026-03-30Platelets [#/volume] in Blood by Automated count40510*3/uL150-400 10*3/uLHighS
2026-03-30Creatinine [Mass/volume] in Serum or Plasma0.76mg/dL0.59-1.04 mg/dLNormalS
2026-03-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-30Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
2026-03-30Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma17U/L7-35 U/LNormalS
2026-03-30Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L8-35 U/LNormalS
2026-03-30Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.45-4.5 mIU/LNormalS
2026-03-30Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
2026-03-30Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-03-30Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S
2026-04-27Hemoglobin [Mass/volume] in Blood12.1g/dL12-15.5 g/dLNormalS
2026-04-27MCV [Entitic mean volume] in Red Blood Cells by Automated count80fL80-100 fLNormalS
2026-04-27Leukocytes [#/volume] in Blood by Automated count6.210*3/uL4-11 10*3/uLNormalS
2026-04-27Platelets [#/volume] in Blood by Automated count35210*3/uL150-400 10*3/uLNormalS
2026-04-27Creatinine [Mass/volume] in Serum or Plasma0.74mg/dL0.59-1.04 mg/dLNormalS
2026-04-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M104mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-27Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
2026-04-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-04-27Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L8-35 U/LNormalS
2026-04-27Thyrotropin [Units/volume] in Serum or Plasma2.2m[IU]/L0.45-4.5 mIU/LNormalS
2026-04-27Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
2026-04-27Carcinoembryonic Ag [Mass/volume] in Serum or Plasma3.4ng/mLUp to 3.0 ng/mL in non-smokersHighS
2026-04-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-06-01Hemoglobin [Mass/volume] in Blood12.6g/dL12-15.5 g/dLNormalS
2026-06-01Leukocytes [#/volume] in Blood by Automated count9.410*3/uL4-11 10*3/uLNormalS
2026-06-01Platelets [#/volume] in Blood by Automated count29010*3/uL150-400 10*3/uLNormalS
2026-06-01Thyrotropin [Units/volume] in Serum or Plasma5.8m[IU]/L0.45-4.5 mIU/LHighS
2026-06-01Thyroxine (T4) free [Mass/volume] in Serum or Plasma1ng/dL0.8-1.8 ng/dLNormalS
2026-06-29Hemoglobin [Mass/volume] in Blood13g/dL12-15.5 g/dLNormalS
2026-06-29Leukocytes [#/volume] in Blood by Automated count610*3/uL4-11 10*3/uLNormalS
2026-06-29Platelets [#/volume] in Blood by Automated count26810*3/uL150-400 10*3/uLNormalS
2026-06-29Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-06-29Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-06-29Creatinine [Mass/volume] in Serum or Plasma0.75mg/dL0.59-1.04 mg/dLNormalS
2026-06-29Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M102mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-06-29Glucose [Mass/volume] in Serum or Plasma89mg/dL70-99 mg/dLNormalS
2026-06-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L7-35 U/LNormalS
2026-06-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-35 U/LNormalS
2026-06-29Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma70U/L35-104 U/LNormalS
2026-06-29Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-06-29Albumin [Mass/volume] in Serum or Plasma4.4g/dL3.5-5 g/dLNormalS
2026-06-29Thyrotropin [Units/volume] in Serum or Plasma12.6m[IU]/L0.45-4.5 mIU/LHighS
2026-06-29Thyroxine (T4) free [Mass/volume] in Serum or Plasma0.6ng/dL0.8-1.8 ng/dLLowS
2026-06-29Carcinoembryonic Ag [Mass/volume] in Serum or Plasma2.1ng/mLUp to 3.0 ng/mL in non-smokersNormalS
2026-06-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-08-10Thyrotropin [Units/volume] in Serum or Plasma3.1m[IU]/L0.45-4.5 mIU/LNormalS
2026-08-10Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
2026-08-10Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-10-05Hemoglobin [Mass/volume] in Blood13.4g/dL12-15.5 g/dLNormalS
2026-10-05MCV [Entitic mean volume] in Red Blood Cells by Automated count86fL80-100 fLNormalS
2026-10-05Leukocytes [#/volume] in Blood by Automated count6.110*3/uL4-11 10*3/uLNormalS
2026-10-05Platelets [#/volume] in Blood by Automated count25510*3/uL150-400 10*3/uLNormalS
2026-10-05Creatinine [Mass/volume] in Serum or Plasma0.77mg/dL0.59-1.04 mg/dLNormalS
2026-10-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M99mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-05Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-35 U/LNormalS
2026-10-05Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L8-35 U/LNormalS
2026-10-05Ferritin [Mass/volume] in Serum or Plasma41ng/mL15-150 ng/mLNormalS
2026-10-05Thyrotropin [Units/volume] in Serum or Plasma2.4m[IU]/L0.45-4.5 mIU/LNormalS
2026-10-05Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
2026-10-05Carcinoembryonic Ag [Mass/volume] in Serum or Plasma1.6ng/mLUp to 3.0 ng/mL in non-smokersNormalS
2026-10-05Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-10-05Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]3{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-03-16Body height168cmS
2026-03-16Body weight62.8kgS
2026-03-16Body mass index (BMI) [Ratio]22.3kg/m2S
2026-03-16Systolic blood pressure112mm[Hg]S
2026-03-16Diastolic blood pressure70mm[Hg]S
2026-03-16Heart rate86/minS
2026-03-16Respiratory rate14/minS
2026-03-16Body temperature36.7CelS
2026-03-16Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-03-30Body height168cmS
2026-03-30Body weight62.6kgS
2026-03-30Body mass index (BMI) [Ratio]22.2kg/m2S
2026-03-30Systolic blood pressure116mm[Hg]S
2026-03-30Diastolic blood pressure72mm[Hg]S
2026-03-30Heart rate80/minS
2026-03-30Respiratory rate14/minS
2026-03-30Body temperature36.6CelS
2026-03-30Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-04-27Body height168cmS
2026-04-27Body weight63.2kgS
2026-04-27Body mass index (BMI) [Ratio]22.4kg/m2S
2026-04-27Systolic blood pressure110mm[Hg]S
2026-04-27Diastolic blood pressure68mm[Hg]S
2026-04-27Heart rate70/minS
2026-04-27Respiratory rate14/minS
2026-04-27Body temperature36.6CelS
2026-04-27Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-06-29Body height168cmS
2026-06-29Body weight63.8kgS
2026-06-29Body mass index (BMI) [Ratio]22.6kg/m2S
2026-06-29Systolic blood pressure114mm[Hg]S
2026-06-29Diastolic blood pressure72mm[Hg]S
2026-06-29Heart rate60/minS
2026-06-29Respiratory rate14/minS
2026-06-29Body temperature36.4CelS
2026-06-29Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-10-05Body height168cmS
2026-10-05Body weight63.4kgS
2026-10-05Body mass index (BMI) [Ratio]22.5kg/m2S
2026-10-05Systolic blood pressure112mm[Hg]S
2026-10-05Diastolic blood pressure70mm[Hg]S
2026-10-05Heart rate64/minS
2026-10-05Respiratory rate14/minS
2026-10-05Body temperature36.6CelS
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-06-01Body height168cmS
2026-06-01Body weight63kgS
2026-06-01Body mass index (BMI) [Ratio]22.3kg/m2S
2026-06-01Systolic blood pressure114mm[Hg]S
2026-06-01Diastolic blood pressure70mm[Hg]S
2026-06-01Heart rate88/minS
2026-06-01Respiratory rate16/minS
2026-06-01Body temperature37.9CelS
2026-06-01Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-08-10Body height168cmS
2026-08-10Body weight63.6kgS
2026-08-10Body mass index (BMI) [Ratio]22.5kg/m2S
2026-08-10Systolic blood pressure112mm[Hg]S
2026-08-10Diastolic blood pressure68mm[Hg]S
2026-08-10Heart rate62/minS
2026-08-10Respiratory rate14/minS
2026-08-10Body temperature36.5CelS
2026-08-10Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
2026-03-16Three months of rectal bleeding, narrower stools and urgency, with tiredness, in a professional golfer of 41: examination, blood tests, and colonoscopy this weekfinishedS
2026-03-30Diagnosis of mismatch repair-deficient low rectal cancer: staging, tumor board plan, medical oncology and colorectal surgery consultation, genetic counseling, and the start of PD-1 blockadefinishedS
2026-04-27Day 1 of cycle 2 of dostarlimab: early response, immune-related adverse event checks, germline and tumor genetic results, iron and anemia, and golffinishedS
2026-06-29Restaging after four doses: pelvic MRI and endoscopy, immune-related hypothyroidism, and the decision to continue PD-1 blockadefinishedS
2026-10-05After nine doses: final restaging, clinical complete response, and the watch-and-wait surveillance planfinishedS
2026-06-01Same-day sick visit for cough and sore throat during immunotherapyfinishedS
2026-08-10Periodic adult preventive visit during immunotherapyfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Medical oncology (gastrointestinal) consultation within two weeks, with colorectal surgery, to review the colonoscopy and any biopsy with her and plan staging and treatment if cancer is foundcompletedGL-NCCN-RECT-2026, GL-ASCO-LARC-2024S
Urgent work-up of rectal bleeding with a change in bowel habit and a rectal mass in a woman under 50: colonoscopy with biopsy within days, with mismatch repair testing of any cancer; blood count, ferritin, chemistry and CEA; if cancer is confirmed, rectal-protocol MRI of the pelvis and CT of the chest, abdomen and pelvis; return at once for heavy bleeding, fainting or inability to pass stoolcompletedGL-NCCN-RECT-2026, GL-USPSTF-CRC-2021S
Oral iron for iron deficiency anemia from blood loss: ferrous sulfate 325 mg on alternate days, a blood count about four weeks after starting, ferritin at about three months, and iron continued for three months after the hemoglobin is normalcompletedGL-CMID-2026S
Germline multigene panel after genetic counseling, because she is under 50 and the tumor is mismatch repair deficient; tumor sequencing for somatic MMR variants if the germline panel is negative; colonoscopy for her first-degree relatives every five years from age 40, or 10 years before the age of her diagnosis if earlier, with Lynch syndrome surveillance only if a germline variant is foundcompletedGL-ASCO-GERM-2024, GL-NCCN-RECT-2026, GL-USMSTF-2017S
Dostarlimab 500 mg intravenously every three weeks for nine doses (six months), with pelvic MRI, flexible sigmoidoscopy and digital rectal examination about every three months; blood count, kidney and liver tests and glucose before each dose and TSH with free T4 every six weeks; teaching about immune-related adverse events with a 24-hour line; hepatitis B, hepatitis C and HIV screening and a pregnancy test first; contraception continued during treatment and for four months aftercompletedGL-NCCN-RECT-2026, GL-ASCO-LARC-2024, GL-CERCEK-2022, GL-CERCEK-2025, GL-ASCO-IRAE-2021, GL-ASCO-HBV-2020S
If the response is incomplete: chemoradiation and total mesorectal excision, as reviewed with the colorectal surgeon, with stoma site marking and teaching by a wound-ostomy nurse before any operation; fertility and sexual function counseling before any pelvic radiationcompletedGL-NCCN-RECT-2026, GL-ASCO-LARC-2024, GL-ASCO-FERT-2018S
Levothyroxine for immune-related hypothyroidism, with TSH and free T4 six weeks after starting and every six weeks while on PD-1 blockade; dostarlimab continuedcompletedGL-ASCO-IRAE-2021, GL-CMID-2026S
Watch-and-wait after a clinical complete response: digital rectal examination and flexible sigmoidoscopy every three to four months and pelvic MRI every six months for two years, CEA every three to six months, CT of the chest, abdomen and pelvis every six to twelve months, colonoscopy at one year, and a written survivorship care plan; surgery at once for any regrowthcompletedGL-NCCN-RECT-2026, GL-CMID-2026, GL-CERCEK-2025S
Distress and depression screening at each visit; plain explanations with written information; attention to sexual health and body image and to her golf, with an exercise plan she sets; she decides who is told and who receives each notecompletedGL-USPSTF-DEP-2023, GL-ASCO-EX-2022S

Goals

GoalTargetStatusOutcomeProvenance
Colonoscopy within one week, staging within two weeks, and a tumor board plan before treatment2026-03-30completedColonoscopy in three days, MRI and CT within nine days, tumor board in eleven days, consultation at two weeksS
Germline genetic testing with counseling, and an explanation of the mismatch repair deficiency, within four weeks of diagnosis2026-04-27completedGermline panel negative; two somatic MSH2 variants in the tumor explain the deficiencyS
Clinical complete response after six months of dostarlimab, with the rectum and sphincter preserved2026-10-05completedClinical complete response on MRI, endoscopy and examination after nine doses; watch-and-wait begunS
Hemoglobin of 12 g/dL or more and ferritin above 30 ng/mL2026-10-05completedHemoglobin 13.4 g/dL and ferritin 41 ng/mLS
Back to tournament golf during treatment2026-06-29completedPlaying 18 holes and entered in a club competition by the fourth visitS
TSH within the reference range on thyroid replacement2026-08-10completedTSH 3.1 mIU/L six weeks after levothyroxine beganS
PHQ-9 below 10 throughout treatment2026-10-05completedPHQ-9 between 2 and 6S

Functional Status

Mental Status